Freestone Grove Partners LP
Position in NBIX — Neurocrine Biosciences Inc
CIK 2007591
San Francisco, CA
Position in NBIX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,580,484
-$18,350,744 QoQ
Shares Held
11,997
-91.5% QoQ
Ownership
0.012%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in NBIX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Freestone Grove Partners LP holds $83,125,705 across 14 Drug Manufacturers - Specialty & Generic names. NBIX ranks #6 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SUPN |
Supernus Pharmaceuticals, Inc.
|
641,319 | $33,149,779 | |
| 2 | ANIP |
Ani Pharmaceuticals Inc
|
254,230 | $19,550,287 | |
| 3 | TEVA |
Teva Pharmaceutical Industries Ltd
|
534,410 | $16,096,429 | |
| 4 | HIMS |
Hims & Hers Health, Inc.
|
229,723 | $4,769,049 | |
| 5 | COLL |
Collegium Pharmaceutical, Inc
|
58,646 | $1,939,423 | |
| 6 | NBIX |
Neurocrine Biosciences Inc
This page
|
11,997 | $1,580,484 | |
| 7 | ZTS |
Zoetis Inc.
|
9,476 | $1,120,157 | |
| 8 | UTHR |
UNITED THERAPEUTICS Corp
|
1,807 | $1,071,514 |
All Filings in NBIX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,580,484 | 11,997 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $19,931,228 | 140,529 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $18,577,608 | 132,338 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $21,132,636 | 168,133 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $576,115 | 5,209 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||